Disorder of peroxisomal alpha-, beta- and omega-oxidation

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Apr 1987

Didronel: FDA approved

Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

1

Copay cards

Copay Assistance1

Didronel

MGI Pharma, Inc.

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Didronel

(Etidronate disodium)Orphan drug

MGI Pharma, Inc.

Approved Apr 1987

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Disorder of peroxisomal alpha-, beta- and omega-oxidation.
Search all trials →
Search clinical trials for Disorder of peroxisomal alpha-, beta- and omega-oxidation

Recent News & Research

No recent news articles indexed yet for Disorder of peroxisomal alpha-, beta- and omega-oxidation.
Search PubMed for Disorder of peroxisomal alpha-, beta- and omega-oxidation

Browse all Disorder of peroxisomal alpha-, beta- and omega-oxidation news →

Specialist Network

No specialists currently listed for Disorder of peroxisomal alpha-, beta- and omega-oxidation.

View all Disorder of peroxisomal alpha-, beta- and omega-oxidation specialists →

Quick Actions